Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer

K. M. Islam, T. Anggondowati, P. E. Deviany, J. E. Ryan, A. Fetrick, D. Bagenda, M. S. Copur, A. Tolentino, I. Vaziri, H. A. McKean, S. Dunder, J. E. Gray, C. Huang, Apar Kishor P Ganti

Research output: Contribution to journalArticle

Abstract

Background: In the U.S., lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices. Methods: An observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression. Results: Patients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy. Conclusions: Patients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.

Original languageEnglish (US)
Article number835
JournalBMC Cancer
Volume19
Issue number1
DOIs
StatePublished - Aug 27 2019

Fingerprint

Patient Preference
Lung Neoplasms
Drug Therapy
Therapeutics
Non-Small Cell Lung Carcinoma
Patient Outcome Assessment
Midwestern United States
Interviews
Patient-Centered Care
Information Storage and Retrieval
Drug-Related Side Effects and Adverse Reactions
Dyspnea
Medical Records
Fatigue
Neoplasms
Cohort Studies
Logistic Models
Hemorrhage
Survival

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. / Islam, K. M.; Anggondowati, T.; Deviany, P. E.; Ryan, J. E.; Fetrick, A.; Bagenda, D.; Copur, M. S.; Tolentino, A.; Vaziri, I.; McKean, H. A.; Dunder, S.; Gray, J. E.; Huang, C.; Ganti, Apar Kishor P.

In: BMC Cancer, Vol. 19, No. 1, 835, 27.08.2019.

Research output: Contribution to journalArticle

Islam, KM, Anggondowati, T, Deviany, PE, Ryan, JE, Fetrick, A, Bagenda, D, Copur, MS, Tolentino, A, Vaziri, I, McKean, HA, Dunder, S, Gray, JE, Huang, C & Ganti, AKP 2019, 'Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer', BMC Cancer, vol. 19, no. 1, 835. https://doi.org/10.1186/s12885-019-6054-x
Islam, K. M. ; Anggondowati, T. ; Deviany, P. E. ; Ryan, J. E. ; Fetrick, A. ; Bagenda, D. ; Copur, M. S. ; Tolentino, A. ; Vaziri, I. ; McKean, H. A. ; Dunder, S. ; Gray, J. E. ; Huang, C. ; Ganti, Apar Kishor P. / Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. In: BMC Cancer. 2019 ; Vol. 19, No. 1.
@article{fe881128f0234ac2ad6e9715d594e495,
title = "Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer",
abstract = "Background: In the U.S., lung cancer accounts for 14{\%} of cancer diagnoses and 28{\%} of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices. Methods: An observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression. Results: Patients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy. Conclusions: Patients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.",
author = "Islam, {K. M.} and T. Anggondowati and Deviany, {P. E.} and Ryan, {J. E.} and A. Fetrick and D. Bagenda and Copur, {M. S.} and A. Tolentino and I. Vaziri and McKean, {H. A.} and S. Dunder and Gray, {J. E.} and C. Huang and Ganti, {Apar Kishor P}",
year = "2019",
month = "8",
day = "27",
doi = "10.1186/s12885-019-6054-x",
language = "English (US)",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer

AU - Islam, K. M.

AU - Anggondowati, T.

AU - Deviany, P. E.

AU - Ryan, J. E.

AU - Fetrick, A.

AU - Bagenda, D.

AU - Copur, M. S.

AU - Tolentino, A.

AU - Vaziri, I.

AU - McKean, H. A.

AU - Dunder, S.

AU - Gray, J. E.

AU - Huang, C.

AU - Ganti, Apar Kishor P

PY - 2019/8/27

Y1 - 2019/8/27

N2 - Background: In the U.S., lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices. Methods: An observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression. Results: Patients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy. Conclusions: Patients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.

AB - Background: In the U.S., lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices. Methods: An observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression. Results: Patients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy. Conclusions: Patients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.

UR - http://www.scopus.com/inward/record.url?scp=85071537628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071537628&partnerID=8YFLogxK

U2 - 10.1186/s12885-019-6054-x

DO - 10.1186/s12885-019-6054-x

M3 - Article

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 835

ER -